KR950702421A - 생활성 조성물, 이것의 제조방법 및 사용방법(novel bioactive compositions, preparation and use thereof) - Google Patents

생활성 조성물, 이것의 제조방법 및 사용방법(novel bioactive compositions, preparation and use thereof) Download PDF

Info

Publication number
KR950702421A
KR950702421A KR1019950700221A KR19950700221A KR950702421A KR 950702421 A KR950702421 A KR 950702421A KR 1019950700221 A KR1019950700221 A KR 1019950700221A KR 19950700221 A KR19950700221 A KR 19950700221A KR 950702421 A KR950702421 A KR 950702421A
Authority
KR
South Korea
Prior art keywords
polyoxyethylene
weight
composition
glycol
lactose
Prior art date
Application number
KR1019950700221A
Other languages
English (en)
Inventor
한가이 기외르기
오라흐 가보르네
토코스 에디트
바모스 기외르기
Original Assignee
가보르네 오라흐, 일디코 에프. 페르게르네
베펙스 케이에프티.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가보르네 오라흐, 일디코 에프. 페르게르네, 베펙스 케이에프티. filed Critical 가보르네 오라흐, 일디코 에프. 페르게르네
Publication of KR950702421A publication Critical patent/KR950702421A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

본 발명은 외음염 및 외음부 질염 증상을 치료 및 완화시키기 위한 약학 조성물에 관한 것이다. 좌약, 연고제, 용액 또는 분무액 형태로 만들어진 본 발명에 따른 조성물은 0.05-0.5 중량%의 폴산, 0.25-2.5 중량%의 판텐올 및/또는 0.15-1.5 중량%의 알란토인, 0.75-7.5 중량%의 단백질 가수분해물 또는 카세인 가수분해물, 3.0-15.0 중량%의 락토스 또는 덱스트로스, 0.25-2.5 중량%의 락트산, 0.25-2.5 중량%의 황산 마그네슘 및 0.75-7.5 중량%의 염화 나트륨 또는 염화 암모늄을 포함한다.

Description

생활성 조성물, 이것의 제조방법 및 사용방법(NOVEL BIOACTIVE COMPOSITIONS, PREPARATION AND USE THEREOF)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 약학적으로 수용될 수 있는 담체 및/또는 보조제화의 혼합물로 0.05-0.5 중량%의 폴산, 0.25-2.5 중량%의 판텐올 및/또는 0.15-1.5 중량%의 알란토인, 0.75-7.5 중량%의 단백질 가수분해물 또는 카세인 가수분해물, 3.0-15.0 중량%의 락토스 또는 덱스트로스, 0.25-2.5 중량%의 락트산, 0.25-2.5 중량%의 황산 마그네슘 및 0.75-7.5 중량%의 염화 나트륨 또는 염화 암모늄을 포함하는, 외음염 또는 외음부 질염의 증상을 치료하기 위한 약학 조성물.
  2. 제1항에 있어서, 약학적으로 수용될 수 있는 담체로서 폴리옥시에틸렌 글리콜 및 폴리옥시에틸렌 소르비탄 지방산 에스테르를 포함하는 것을 특징으로 하는 조성물.
  3. 제1항에 있어서, 0.05-0.1 중량%의 폴산, 0.8-1.5 중량%의 단백질 가수분해물, 8-14 중량%의 락토스, 1.0-2.0 중량%의 락트산, 1.0-2.1 중량%의 황산 마그네슘, 2.0-4.0 중량%의 염화 나트륨 또는 염화 암모늄, 60.0-68.0 중량%의 폴리옥시에틸렌-글리콜 1540 및 10-15 중량%의 폴리옥시에틸렌-글리콜 모노라우레이트를 포함하는 것을 특징으로 하는 좌약 조성물.
  4. 제1항에 있어서, 02 중량%의 d-판텐올, 0.75-1.5 중량%의 단백질 가수분해물, 7-12.0 중량%의 락토스, 0.5-2.0 중량%의 락트산, 0.1-0.5 중량%의 황산 마그네슘, 6.0-10.0 중량%의 폴리옥시에틸렌 글리콜 모노라우레이트, 25-70.0 중량%의 폴리옥시에틸렌 글리콜 400 및 0.5-51.0 중량%의 폴리옥시에틸렌 글리콜 1540을 포함하는 것을 특징으로 하는 연고제 조성물.
  5. 제1항에 있어서, 0.2-1.0 중량%의 d-판텐올, 0.6-2.0 중량%의 단백질 가수분해물, 5.0-10.0 중량%의 락토스, 0.5-1.0 중량%의 락트산, 0.3-0.5 중량%의 황산 마그네슘, 2.0-3.0 중량%의 염화 나트륨, 44.5-55.0 중량%의 폴리옥시에틸렌 글리콜 400, 7.5-12.0 중량%의 폴리옥시에틸렌 글리콜 모노라우레이트 뿐만 아니라 19.0-33 중량%의 증류수를 포함하는 것을 특징으로 하는 용액 또는 분무액 조성물.
  6. 0.05-0.5 중량%의 폴산, 0.25-2.5 중량%의 판텐올 및/또는 0.15-1.5 중량%의 알란토인, 0.75-7.5 중량%의 단백질 가수분해물 또는 카세인 가수분해물, 3.0-15.0 중량%의 락토스 또는 덱스트로스, 0.25-2.5 중량%의 락트산, 0.25-2.5 중량%의 황산 마그네슘 및 0.75-7.5 중량%의 염화 나트륨 또는 염화 암모늄과 약학적으로 수용될수 있는 담체 및/또는 보조물질을 혼합시키는 단계; 그리고 이 혼합물을 외음부 질염 또는 외음염의 증상의 치료 또는 완화를 위해 각각 사용될 수 있는 좌약, 연고제, 용액 또는 분무액으로 형성시키는 단계로 이루어지는 약학 조성물의 제조방법.
  7. 제6항에 있어서, 약학적으로 수용될 수 있는 담체로서 폴리옥시에틸렌-글리콜 및 폴리옥시에틸렌-글리콜 소르비탄 지방산 에스테르를 사용함을 특징으로 하는 방법.
  8. 제1항 내지 3항중 어느 한 항에 있어서의 조성물을, 매일 3.5-4.0g의 투여량으로, 적합하게는 좌약형태로 환자에게 투약하는 것을 특징으로 하는, 외음부 질염 및 외음염 증상의 치료 뿐만 아니라 이러한 건강 손상을 예방하는 방법.
  9. 외음염 및 외음부 질염 증상을 완화시키거나 이러한 손상을 예방하기 위해 제1항 내지 5항중 어느 한 항에 있어서의 조성물을 사용하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950700221A 1992-07-22 1993-03-18 생활성 조성물, 이것의 제조방법 및 사용방법(novel bioactive compositions, preparation and use thereof) KR950702421A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP9202398 1992-07-22
HU9202398A HU212426B (en) 1992-07-22 1992-07-22 Process for producing bioactive pharmaceutical compositions
PCT/HU1993/000016 WO1994002148A1 (en) 1992-07-22 1993-03-18 Novel bioactive compositions, preparation and use thereof

Publications (1)

Publication Number Publication Date
KR950702421A true KR950702421A (ko) 1995-07-29

Family

ID=10982190

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950700221A KR950702421A (ko) 1992-07-22 1993-03-18 생활성 조성물, 이것의 제조방법 및 사용방법(novel bioactive compositions, preparation and use thereof)

Country Status (18)

Country Link
US (1) US5622927A (ko)
EP (1) EP0651641B1 (ko)
JP (1) JPH08501533A (ko)
KR (1) KR950702421A (ko)
AT (1) ATE170752T1 (ko)
AU (1) AU688260B2 (ko)
BG (1) BG62036B1 (ko)
CA (1) CA2140630A1 (ko)
CZ (1) CZ283011B6 (ko)
DE (1) DE69320968T2 (ko)
FI (1) FI950290A0 (ko)
HU (1) HU212426B (ko)
NZ (1) NZ251424A (ko)
PL (1) PL171031B1 (ko)
RO (1) RO111735B1 (ko)
RU (1) RU2117479C1 (ko)
SK (1) SK279276B6 (ko)
WO (1) WO1994002148A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1062111C (zh) * 1995-12-06 2001-02-21 李启荣 杂交水稻制种花期花时调节剂
US5750122A (en) * 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
ATE306274T1 (de) * 1997-11-24 2005-10-15 Zhongming Zeng Verwendung von dextrin, stärke oder glykogen zur behandlung von bakterieller vaginosis
US6964949B2 (en) 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
ITMI20010913A1 (it) * 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
US8118789B2 (en) * 2002-02-20 2012-02-21 Abbott Research Group, Inc. Deodorizer devices and systems for controlling perspiration-related body odor
US7270653B2 (en) * 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US6589216B1 (en) 2002-02-20 2003-07-08 Abbott Research Group, Inc. Vaginal douches, vaginal douche applicators and methods of vaginal douching
US20050271746A1 (en) * 2004-05-18 2005-12-08 Abbott Chun L Topical treatments for abnormal biological conditions and method of topically treating such conditions
JP4807972B2 (ja) * 2005-06-01 2011-11-02 株式会社池田模範堂 皮膚外用剤
KR101133723B1 (ko) * 2009-10-19 2012-04-09 최원석 소금 및 당을 유효성분으로 함유하는 질염 예방 및 치료용 조성물 및 이의 용도
US9220751B2 (en) * 2010-04-21 2015-12-29 Mileutis Ltd. Casein peptide for use in the treatment of uterine infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE35991B1 (en) * 1971-01-22 1976-07-21 Comprehensive Pharmaceuticals Improvements in or relating to the treatment of diseases of the skin and mucosa
DE3011437A1 (de) * 1980-03-25 1981-10-01 Hrvoje Dr. Zagreb Krnjevic Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen
US4393066A (en) * 1981-06-05 1983-07-12 Garrett David M Method for treatment of herpetic lesions
US4628063A (en) * 1984-03-08 1986-12-09 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4665069A (en) * 1985-04-02 1987-05-12 Barnett Rosenberg Analgesic composition and method of relieving pain
WO1988004927A1 (en) * 1986-12-31 1988-07-14 Davirand, Inc. Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface

Also Published As

Publication number Publication date
DE69320968T2 (de) 1999-04-15
DE69320968D1 (de) 1998-10-15
CZ283011B6 (cs) 1997-12-17
AU688260B2 (en) 1998-03-12
BG62036B1 (bg) 1999-01-29
PL307256A1 (en) 1995-05-15
CA2140630A1 (en) 1994-02-03
SK7795A3 (en) 1995-07-11
HU9202398D0 (en) 1992-10-28
FI950290A (fi) 1995-01-23
US5622927A (en) 1997-04-22
RO111735B1 (ro) 1997-01-30
AU3903193A (en) 1994-02-14
CZ15395A3 (en) 1995-09-13
JPH08501533A (ja) 1996-02-20
BG99360A (bg) 1995-12-29
HUT64840A (en) 1994-03-28
ATE170752T1 (de) 1998-09-15
RU2117479C1 (ru) 1998-08-20
EP0651641A1 (en) 1995-05-10
WO1994002148A1 (en) 1994-02-03
EP0651641B1 (en) 1998-09-09
SK279276B6 (sk) 1998-09-09
FI950290A0 (fi) 1995-01-23
PL171031B1 (pl) 1997-02-28
NZ251424A (en) 1997-06-24
HU212426B (en) 1996-06-28

Similar Documents

Publication Publication Date Title
KR950702421A (ko) 생활성 조성물, 이것의 제조방법 및 사용방법(novel bioactive compositions, preparation and use thereof)
KR940005285A (ko) 염증성 장 질환, 염증성 피부 질환 및 자반증의 예방 및 치료용 약제제조를 위한 상보적 억제제의 용도
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
DE60109938D1 (de) Zusammenstellungen die aktive stilbenoidverbindungen enthalten zur senkung des triglyceridspiegels
DE69217112D1 (de) Phenyl-pyrazolidinone als Bronchodilatatoren und entzündungshemmende Mittel
WO2003017936A2 (en) Use of dppiv inhibitors as diuretic and anti-hypertensive agents
DE3687429D1 (de) Gamma-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen.
KR920009389A (ko) 외용 피부학적 조성물
ATE245979T1 (de) Behandlung der pulmonalen hypertension durch inhalation von benzinden-prostaglandine
LV12766A (lv) Composition of l-dopa esters
AR027533A1 (es) Derivados de acido malonico, procesos para su preparacion, su uso y composiciones farmaceuticas que los contienen
ATE311765T1 (de) Mischung enthaltend procyanidine zur verminderung des appetits bei säugetieren
RU95109159A (ru) Новые биологически активные композиции, их получение и применение
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
DE60036862D1 (de) Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid-analoge
DE60116302D1 (de) Behandlung von seborrhoischer dermatitis
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
US4181731A (en) Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
AU1870097A (en) Use of a medicament and use of mixture of substances to produce a medicament
SV1996000001A (es) Nuevas aplicaciones de dimero de lisozima
NO952900D0 (no) Kompositt inneholdende tandospiron eller analoger av samme
ATE92756T1 (de) Mittel zur behandlung von keratose.
MY111140A (en) Phenoxyphenyl cyclopentenyl hydroxyureas.
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid